| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5814200 | Neuropharmacology | 2014 | 18 Pages |
Abstract
The results demonstrate that the GLP-1 receptor agonists liraglutide and lixisenatide which are on the market as treatments for type 2 diabetes show promise as potential drug treatments of AD. Lixisenatide was equally effective at a lower dose compared to liraglutide in some of the parameters measured.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Paula L. McClean, Christian Hölscher,